Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorasidenib in Residual or Recurrent Grade 2 IDH-Mutant Glioma
2024-512961-15-00Phase 3Authorised
- Sponsor
- Servier
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in glioma, astrocytoma and Oligodendroglioma (OG) comparing Vorasidenib with Placebo (2 arms). Primary endpoint: Radiographic progression-free survival (PFS) by BIRC. Planned start Jul 2024; status: authorised.
02
Drugs
vorasidenib
03
Conditions
gliomaastrocytomaOligodendroglioma (OG)
Beyond the preview
Go deeper on 2024-512961-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512961-15-00.